Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top medical journals. CAMBRIDGE, Mass., Oct. 15, 2025 ...

When robotics and cloud-connected digital twins work in sync, they create a living, responsive system that continually ...

Until recently, the most effective protection against respiratory syncytial virus (RSV) was only available for high-risk infants, and many parents and providers may remember the vulnerability that ...

Inovalon, a leading provider of data and solutions empowering data-driven healthcare, announced its real-world data and analytics supported Forbes’ inaugural Top Hospitals List & Ratings, released ...

Amtagvi shows a 48.8% ORR in advanced melanoma, with higher efficacy in less heavily treated patients. FDA granted accelerated approval for Amtagvi in 2024 for unresectable or metastatic melanoma ...